Why This Massachusetts Synthetic Bio Startup Could be the Next Biotech Unicorn Post author:Sam Post published:December 11, 2017 Post category:BioPharma In investment jargon, a “unicorn” has at least two meanings. Source: BioSpace You Might Also Like Sanofi's Rumored Buyout Target Flexion Shows Off Mid-Stage Osteoarthritis Data June 11, 2017 Pharma Giant Merck & Co. Considering 600-Job IT Hub in Austin April 5, 2017 Why Boston-Bound Alexion Could be a Compelling M&A for Larger Drugmakers January 29, 2018
